Faced with a shortened financial runway and trial recruitment obstacles caused by the COVID-19 crisis, Nordic Nanovector ASA will cut staff by 20% and pause all clinical activities other than its key pivotal PARADIGME study which is evaluating lead asset Betalutin (177Lu lilotomab satetraxetan) in third-line relapsed/refractory follicular lymphoma.
The Norway-based biotech is advancing Betalutin in the global, randomized Phase IIb trial as a first-to-market treatment for in third-line...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?